Merck Highlights Positive Enpatoran Phase 2 WILLOW Study Data in SLE at EULAR 2025 Merck, a leading science and technology company, today presented new and detailed results from its Phase 2 WILLOW study, emphasizing the potential of its investigational oral…
EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and sustained reduction in disease flares and key disease activity markers…
Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive new findings from their Phase 3 PHOENYCS GO clinical trial…
WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health Organization (WHO) convened the fourth meeting of the International Health…
WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN Pharmaceuticals (HKEX: 2561), a clinical-stage biopharmaceutical company dedicated to advancing…
Sanofi Ramps Up Early Global Distribution of Beyfortus to Meet Growing RSV Season Demand, Enhancing Protection for Infants Worldwide In a proactive move to ensure readiness for the 2025-2026 respiratory syncytial virus (RSV) season, Sanofi has announced that shipments of…
WHO Advances Global Chemical Hazard Preparedness with New Comprehensive Online Training Series In a recent address to the Seventy-eighth World Health Assembly, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), brought critical attention to an often-overlooked public…
Bayer’s Nubeqa Secures Third FDA Approval, Expanding Prostate Cancer Treatment Landscape Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted approval for a third indication of its oral androgen receptor inhibitor, Nubeqa™ (darolutamide). This latest approval…
Eli Lilly Presents Promising Phase 1 Data for Investigational FRα-Targeting ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025 Eli Lilly and Company has announced encouraging new Phase 1 clinical data for its investigational folate receptor alpha (FRα) targeting antibody-drug conjugate…
Protagonist Therapeutics and Takeda Reveal Comprehensive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera at ASCO 2025 Protagonist Therapeutics,and Takeda Pharmaceutical Company Limited have announced detailed findings from the Phase 3 VERIFY clinical trial evaluating rusfertide, an investigational…
Merck’s Zilovertamab Vedotin in Combination With R-GemOx Shows Promising Efficacy in Relapsed/Refractory DLBCL Patients: Phase 2 Results from waveLINE-003 Trial Presented at ASCO 2025 Merck, known as MSD outside the United States and Canada, has unveiled encouraging new clinical data…
Global Unity, Historic Milestones: 78th World Health Assembly Concludes with Ambitious Health Agenda The Seventy-eighth World Health Assembly (WHA78), the flagship decision-making forum of the World Health Organization (WHO), drew to a close on May 27, 2025, marking what many…